Clinical Trial: The efficacy and safety of hierarchical collateral artery embolization (TAE) and sequential hepatic artery infusion chemotherapy (HAIC) in the treatment of unresectable primary hepatocellular carcinoma: a prospective real-world study (China)

Posted On: 2026-09-07

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The efficacy and safety of hierarchical collateral artery embolization (TAE) and sequential hepatic artery infusion chemotherapy (HAIC) in the treatment of unresectable primary hepatocellular carcinoma: a prospective real-world study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131652

Registration Time: 2026/09/04

Type: Observational study

Primary Sponsor: Jiangjin Central Hospital of Chongqing

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=294571

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: The efficacy and safety of hierarchical collateral artery embolization (TAE) and sequential hepatic artery infusion chemotherapy (HAIC) in the treatment of unresectable primary hepatocellular carcinoma: a prospective real-world study (China)